Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance

Immunological Reviews

Volumn 280, Issue 1, 2017, Pages 165-174

  Bloy, Norma ^a,b,c,d,e,f   Garcia, Pauline ^c,e,f   Laumont, Céline M ^g,h   Pitt, Jonathan M ^a,i,j   Sistigu, Antonella ^k   Stoll, Gautier ^a,b,c,d   Yamazaki, Takahiro ^j   Bonneil, Eric ^g   Buqué, Aitziber ^a,b,c,d,e   Humeau, Juliette ^a,b,c,d,e,f   Drijfhout, Jan W ^l,m   Meurice, Guillaume ⁿ   Walter, Steffen ^o   Fritsche, Jens ^o   Weinschenk, Toni ^o   Rammensee, Hans Georg ^p   Melief, Cornelis ^q   Thibault, Pierre ^g,h   Perreault, Claude ^g,h,r   Pol, Jonathan ^a,b,c,d,e   Zitvogel, Laurence ⁱ   Senovilla, Laura ^a,b,c,d   Kroemer, Guido ^{a,b,c,d,e,s,t}   more..

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c INSERM   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^h UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ Center of Clinical Investigations in Biotherapies of Cancer   (France)

^j University Paris XI   (France)

^k REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^l LEIDEN UNIVERSITY   (Netherlands)

^m Medical Center   (Netherlands)

ⁿ CNRS UMS3655   (France)

^o IMMATICS BIOTECHNOLOGIES GMBH   (Germany)

^p UNIVERSITY OF TÜBINGEN   (Germany)

^q ISA Pharmaceuticals   (Netherlands)

^r MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^s HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^t KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

autophagy; calreticulin; endoplasmic reticulum stress; hyperploidy; immunopeptidome

Indexed keywords

CALRETICULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE VACCINE; ADENOSINE TRIPHOSPHATE; IMMUNOLOGICAL ADJUVANT; TUMOR ANTIGEN;

ADJUVANTICITY; ANTIGEN RECOGNITION; ANTIGENICITY; APOPTOSIS; AUTOPHAGY; CANCER CELL; CANCER IMMUNIZATION; CANCER INHIBITION; CELL STRESS; CELL SURFACE; CELLULAR IMMUNITY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPETENCE; IMMUNOPEPTIDOME; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MASS SPECTROMETRY; NONHUMAN; PEPTIDE ANALYSIS; POLYPLOIDY; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; TUMOR IMMUNOGENICITY; TUMOR MICROENVIRONMENT; ANIMAL; CELL DEATH; ENDOPLASMIC RETICULUM STRESS; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; METABOLISM; MOUSE; NEOPLASM; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; CELL DEATH; ENDOPLASMIC RETICULUM STRESS; HUMANS; IMMUNOLOGIC SURVEILLANCE; MICE; MONITORING, IMMUNOLOGIC; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 85031104045     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12582     Document Type: Review

References (66)

1. Palucka AK, Coussens LM. The basis of oncoimmunology. Cell. 2016;164:1233-1247.
2. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235-271.
3. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565-1570.
4. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat Rev Immunol. 2006;6:715-727.
5. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer. 2012;12:298-306.
6. Becht E, Giraldo NA, Germain C, et al. Immune contexture, immunoscore, and malignant cell molecular subgroups for prognostic and theranostic classifications of cancers. Adv Immunol. 2016;130:95-190.
7. Senovilla L, Vitale I, Martins I, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science. 2012;337:1678-1684.
8. Vacchelli E, Ma Y, Baracco EE, et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science. 2015;350:972-978.
9. Rusakiewicz S, Semeraro M, Sarabi M, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 2013;73:3499-3510.
10. Zitvogel L, Rusakiewicz S, Routy B, Ayyoub M, Kroemer G. Immunological off-target effects of imatinib. Nat Rev Clin Oncol. 2016;13:431-446.
11. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell. 2015;161:205-214.
12. Topalian SL, Wolchok JD, Chan TA, et al. Immunotherapy: The path to win the war on cancer? Cell. 2015;161:185-186.
13. Matzinger P. The danger model: A renewed sense of self. Science. 2002;296:301-305.
14. Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515:577-581.
15. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69-74.
16. Yadav M, Jhunjhunwala S, Phung QT, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515:572-576.
17. Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu Rev Immunol. 2015;33:445-474.
18. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189-2199.
19. McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463-1469.
20. Bianchi ME. DAMPs, PAMPs and alarmins: All we need to know about danger. J Leukoc Biol. 2007;81:1-5.
21. Mackey D, McFall AJ. MAMPs and MIMPs: Proposed classifications for inducers of innate immunity. Mol Microbiol. 2006;61:1365-1371.
22. Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and anticancer immunosurveillance. Cell. 2016;165:276-287.
23. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell. 2010;140:798-804.
24. Elliott MR, Chekeni FB, Trampont PC, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature. 2009;461:282-286.
25. Michaud M, Martins I, Sukkurwala AQ, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science. 2011;334:1573-1577.
26. Gardai SJ, McPhillips KA, Frasch SC, et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005;123:321-334.
27. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54-61.
28. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050-1059.
29. Sistigu A, Yamazaki T, Vacchelli E, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20:1301-1309.
30. Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860-875.
31. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51-72.
32. Kepp O, Senovilla L, Vitale I, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014;3:e955691.
33. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97-111.
34. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202:1691-1701.
35. Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29:482-491.
36. Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19:5720-5728.
37. Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med. 2013;368:651-662.
38. Ladoire S, Enot D, Senovilla L, et al. The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. Autophagy. 2016;12:864-875.
39. Pietrocola F, Pol J, Vacchelli E, et al. Caloric restriction mimetics enhance anticancer immunosurveillance. Cancer Cell. 2016;30:147-160.
40. Pietrocola F, Pol J, Vacchelli E, et al. Autophagy induction for the treatment of cancer. Autophagy. 2016;12:1962-1964.
41. Martins I, Wang Y, Michaud M, et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ. 2014;21:79-91.
42. Munz C. Autophagy proteins in antigen processing for presentation on MHC molecules. Immunol Rev. 2016;272:17-27.
43. Bloy N, Sauvat A, Chaba K, et al. Morphometric analysis of immunoselection against hyperploid cancer cells. Oncotarget. 2015;6:41204-41215.
44. Boileve A, Senovilla L, Vitale I, et al. Immunosurveillance against tetraploidization-induced colon tumorigenesis. Cell Cycle. 2013;12:473-479.
45. Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017;355. pii: eaaf8399.
46. Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: A mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol. 2011;12:385-392.
47. Senovilla L, Demont Y, Humeau J, Bloy N, Kroemer G. Image cytofluorometry for the quantification of ploidy and endoplasmic reticulum stress in cancer cells. Methods Mol Biol. 2017;1524:53-64.
48. Panaretakis T, Joza N, Modjtahedi N, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ. 2008;15:1499-1509.
49. Panaretakis T, Kepp O, Brockmeier U, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 2009;28:578-590.
50. Harding HP, Zhang Y, Zeng H, et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell. 2003;11:619-633.
51. Pakos-Zebrucka K, Koryga I, Mnich K, et al. The integrated stress response. EMBO Rep. 2016;17:1374-1395.
52. Pamer E, Cresswell P. Mechanisms of MHC class I–restricted antigen processing. Annu Rev Immunol. 1998;16:323-358.
53. van Endert PM. Genes regulating MHC class I processing of antigen. Curr Opin Immunol. 1999;11:82-88.
54. Michaud M, Sukkurwala AQ, Martins I, et al. Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39. Oncoimmunology. 2012;1:393-395.
55. Ma Y, Galluzzi L, Zitvogel L, Kroemer G. Autophagy and cellular immune responses. Immunity. 2013;39:211-227.
56. Ko A, Kanehisa A, Martins I, et al. Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling. Cell Death Differ. 2014;21:92-99.
57. Rao HS, Kamalraj M. Synthesis and characterization of 4-aryl-4H-chromenes from H-cardanol. Nat Prod Commun. 2014;9:1333-1340.
58. Ladoire S, Penault-Llorca F, Senovilla L, et al. Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. Autophagy. 2015;11:1878-1890.
59. Galluzzi L, Pedro JM, Demaria S, Formenti SC, Kroemer G. Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy. Nat Rev Clin Oncol. 2016;14:247-258.
60. Martins I, Tesniere A, Kepp O, et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle. 2009;8:3723-3728.
61. Ma Y, Adjemian S, Mattarollo SR, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013;38:729-741.
62. Tey SK, Khanna R. Autophagy mediates transporter associated with antigen processing-independent presentation of viral epitopes through MHC class I pathway. Blood. 2012;120:994-1004.
63. Oliveira CC, van Hall T. Alternative antigen processing for MHC class I: Multiple roads lead to Rome. Front Immunol. 2015;6:298.
64. Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012;18:1254-1261.
65. Chen X, Fosco D, Kline DE, Kline J. Calreticulin promotes immunity and type I interferon-dependent survival in mice with acute myeloid leukemia. Oncoimmunology. 2017;6:e1278332.
66. Caron E, Vincent K, Fortier MH, et al. The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation. Mol Syst Biol. 2011;7:533.